OS THERAPIES INCORPORATED Earnings Per Share (Diluted)
OS THERAPIES INCORPORATED (OSTX) reported Earnings Per Share (Diluted) of -$0.20 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-14
- OS THERAPIES INCORPORATED earnings per share, diluted for the quarter ending 2026-06-30 was -$0.20.
- OS THERAPIES INCORPORATED earnings per share, diluted for the quarter ending 2026-03-31 was -$0.27.
- OS THERAPIES INCORPORATED earnings per share, diluted for the quarter ending 2025-12-31 was -$0.39.
- OS THERAPIES INCORPORATED earnings per share, diluted for the quarter ending 2025-09-30 was -$0.21.
- OS THERAPIES INCORPORATED earnings per share, diluted for fiscal 2025 was -$0.98.
- OS THERAPIES INCORPORATED earnings per share, diluted for fiscal 2024 was -$1.28.
- OS THERAPIES INCORPORATED earnings per share, diluted for fiscal 2023 was -$1.46.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$0.20 10-Q · filed 2026-08-14 | -$0.46 10-Q · filed 2026-08-14 | -$0.83 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-08-14 | |
| 2026-03-31 | -$0.27 10-Q · filed 2026-05-18 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.87 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$1.08 derived: net income ÷ weighted average shares · filed 2026-08-14 | |
| 2025-12-31 | -$0.39 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$0.61 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$0.81 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.98 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$0.21 10-Q · filed 2025-11-14 | -$0.40 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.57 10-Q · filed 2025-11-14 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-08-14 | |
| 2025-06-30 | -$0.19 10-Q · filed 2026-08-14 | -$0.35 10-Q · filed 2026-08-14 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.92 derived: net income ÷ weighted average shares · filed 2026-08-14 | |
| 2025-03-31 | -$0.18 10-Q · filed 2026-05-18 | -$0.64 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.79 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-08-14 | |
| 2024-12-31 | -$59.18 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$1.02 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$1.28 10-K · filed 2026-03-31 | -$0.88 10-K · filed 2025-03-31 |
| 2024-09-30 | -$0.18 10-Q · filed 2025-11-14 | -$0.41 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$0.64 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | -$0.26 10-Q · filed 2025-08-18 | -$0.52 10-Q · filed 2025-08-18 | |||
| 2024-03-31 | -$0.25 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | -$1.46 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$0.38 10-Q · filed 2024-11-15 | -$0.84 derived: net income ÷ weighted average shares · filed 2024-11-15 | -$0.61 10-Q · filed 2024-11-15 | ||
| 2023-06-30 | -$0.47 10-Q · filed 2024-08-14 | -$0.83 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |